DAR Up to 85! An In-Depth Look at the ADC Platform Patents Behind Xinge
Xinge Corporation (headquartered in Nagoya, Aichi Prefecture, Japan) recently announced that non-clinical data for its novel antibody-drug conjugate (ADUC) K-679 will be officially presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled to take place from April 25 to 30, 2025, in Chicago, Illinois, USA. K-679 K-679 is an antibody-drug conjugate … Read more